Head-To-Head Contrast: CytomX Therapeutics (NASDAQ:CTMX) & Anthera Pharmaceuticals (OTCMKTS:ANTH)

Anthera Pharmaceuticals (OTCMKTS:ANTH) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Analyst Recommendations

This is a summary of recent ratings and price targets for Anthera Pharmaceuticals and CytomX Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthera Pharmaceuticals	0	0	0	0	0.00
CytomX Therapeutics	1	0	9	0	2.80

CytomX Therapeutics has a consensus price target of $13.44, indicating a potential upside of 236.11%. Given CytomX Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Anthera Pharmaceuticals.

Insider & Institutional Ownership

67.8% of CytomX Therapeutics shares are owned by institutional investors. 2.1% of Anthera Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Anthera Pharmaceuticals and CytomX Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anthera Pharmaceuticals	N/A	N/A	N/A
CytomX Therapeutics	-22.79%	-19.77%	-11.91%

Valuation & Earnings

This table compares Anthera Pharmaceuticals and CytomX Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CytomX Therapeutics	$76.20 million	8.93	-$17.37 million	($0.04)	-100.00

Anthera Pharmaceuticals has higher earnings, but lower revenue than CytomX Therapeutics.

Risk & Volatility

Anthera Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.

Summary

CytomX Therapeutics beats Anthera Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

About CytomX Therapeutics

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.